.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,635,485

« Back to Dashboard

Claims for Patent: 5,635,485

Title: Erythromycin compounds
Abstract:An erythromycin compound of Formula I or its non-toxic acid addition salt having antibiotic activity.
Inventor(s): Agouridas; Constantin (Nogent sur Maine, FR), Chantot; Jean-Francois (Nogent sur Maine, FR), Denis; Alexis (Paris, FR), D'Ambrieres; Solange G. (Paris, FR), Martret; Odile L. (Paris, FR)
Assignee: Roussel Uclaf (FR)
Application Number:08/426,067
Patent Claims: 1. A compound of the formula ##STR27## wherein R is ##STR28## or --(CH.sub.2).sub.n --Ar, n is an integer from 3 to 5, Ar is an optionally substituted heterocyclic selected from the group consisting of ##STR29## the optional substituents are at least one member selected from the group consisting of a free, salified, esterified and amidified carboxyl, hydroxyl, halogen, --NO.sub.2, --CN, alkyl, cycloalkyl, alkenyl, alkynyl, O-alkyl, O-alkenyl, O-alkynyl, S-alkyl, S-alkenyl, S-alkynyl, N-alkyl, N-alkenyl and N-alkynyl of up to 12 carbon atoms optionally substituted by one or more halogens, ##STR30## R.sub.1 and R.sub.2 are individually hydrogen or alkyl of up to 12 carbon atoms, ##STR31## R.sub.3 is alkyl of up to 12 carbon atoms, and d) an optionally substituted carbocyclic O-aryl and S-aryl and heterocyclic aryl, O-aryl and S-aryl and Z is hydrogen or an acid remainder or its non-toxic, pharmaceutically acceptable acid addition salts.

2. A compound of claim 1 wherein Z is hydrogen.

3. A compound of claim 1 wherein Z is 4.

4. A compound of claim 1 wherein Ar is ##STR32## optionally substituted.

5. A compound of claim 1 wherein Ar is ##STR33## optionally substituted.

6. A compound of claim 1 wherein Ar is selected from the group consisting of ##STR34## optionally substituted.

7. A compound of claim 1 wherein Ar is ##STR35## optionally substituted.

8. A compound of claim 1 selected from the group consisting of

11,12-dideoxy-3-de-[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopy ranosyl)-oxy)-6-O-methyl-3-oxo-12,11-(oxycarbonyl-((4-(4-phenyl-1H-imidazol -1-yl)-butyl)-imino)]-erythromycin,

11,12-dideoxy-3-de-[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopy ranosyl)-oxy)-6-O-methyl-3-oxo-12,11-(oxycarbonyl-((4-(3H-imidazo(4,5-b)pyr idin-3-yl)-butyl)-imino)]-erythromycin,

11,12-dideoxy-3-de-[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopy ranosyl)-oxy)-6-O-methyl-3-oxo-12,11-(oxycarbonyl-((4-(1H-imidazo(4,5-b)pyr idin-1-yl)-butyl)-imino)]-erythromycin,

11,12-dideoxy-3-de-[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopy ranosyl)-oxy)-6-O-methyl-3-oxo-12,11-(oxycarbonyl-((4-(4-(4-chlorophenyl)-1 H-imidazol-1-yl)-butyl)-imino)]-erythromycin,

11,12-dideoxy-3-de-[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopy ranosyl)-oxy)-6-O-methyl-3-oxo-12,11-(oxycarbonyl-((4-(4-(2-methoxyphenyl)- 1H-imidazol-1-yl)-butyl)-imino)]-erythromycin,

11,12-dideoxy-3-de-[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopy ranosyl)-oxy)-6-O-methyl-3-oxo-12,11-(oxycarbonyl-((4-(4-(4-fluorophenyl)-1 H-imidazol-1-yl)-butyl)-imino)]-erythromycin,

11,12-dideoxy-3-de-[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopy ranosyl)-oxy)-6-O-methyl-3-oxo-12,11-(oxycarbonyl-((4-(7-methoxy-4-quinolei nyl)-butyl)-imino)]-erythromycin,

11,12-dideoxy-3-de-[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopy ranosyl)-oxy)-6-O-methyl-3-oxo-12,11-(oxycarbonyl-((4-(2-(2-pyridinyl)-4-th iazolyl)-butyl)-imino)]-erythromycin,

11. 12-dideoxy-3-de-[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexop yranosyl)-oxy)-6-O-methyl-3-oxo-12,11-(oxycarbonyl-((4-(3-(3-pyridinyl)-1H- 1,2,4-triazol-1-yl)-butyl)-imino)]-erythromycin,

and their non-toxic, pharmaceutically acceptable acid addition salts.

9. A compound of claim 1 which is 11,12-dideoxy-3-de-[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexop yranosyl)-oxy)-6-O-methyl-3-oxo-12,11-(oxycarbonyl-((4-(4-(3-pyridinyl)-1H- imidazol-1-yl)-butyl)-imino)]-erythromycin.

10. An antibacterial composition comprising an antibiotically effective amount of a compound of claim 1 and an inert pharmaceutical carrier.

11. A method of treating bacterial infections in warm-blooded animals comprising administering to warm-blooded animals having a bacterial infection an antibiotically effective amount of a compound of claim 1.

12. A method of claim 11 wherein Z is hydrogen.

13. A method of claim 11 wherein n is 4.

14. A method of claim 11 wherein Ar is ##STR36## optionally substituted.

15. A method of claim 11 wherein Ar is ##STR37## optionally substituted.

16. A method of claim 11 wherein Ar is selected from the group consisting of ##STR38## optionally substituted.

17. A method of claim 11 wherein Ar is ##STR39## optionally substituted.

18. A method of claim 11 wherein the compound is selected from the group consisting of

11,12-dideoxy-3-de-[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopy ranosyl)-oxy)-6-O-methyl-3-oxo-12,11-(oxycarbonyl-((4-(4-phenyl-1H-imidazol -1-yl)-butyl)-imino)]-erythromycin,

11,12-dideoxy-3-de-[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopy ranosyl)-oxy)-6-O-methyl-3-oxo-12,11-(oxycarbonyl-((4-(3H-imidazo(4,5-b)pyr idin-3-yl)-butyl)-imino)]-erythromycin,

11. 12-dideoxy-3-de-[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexop yranosyl)-oxy)-6-O-methyl-3-oxo-12,11-(oxycarbonyl-((4-(1H-imidazo(4,5-b)py ridin-1-yl)-butyl)-imino)]-erythromycin,

11,12-dideoxy-3-de-[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopy ranosyl)-oxy)-6-O-methyl-3-oxo-12,11-(oxycarbonyl-((4-(4-(4-chlorophenyl)-1 H-imidazol-1-yl)-butyl)-imino)]-erythromycin,

11,12-dideoxy-3-de-[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopy ranosyl)-oxy)-6-O-methyl-3-oxo-12,11-(oxycarbonyl-((4-(4-(2-methoxyphenyl)- 1H-imidazol-1-yl)-butyl)-imino)]-erythromycin,

11,12-dideoxy-3-de-[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopy ranosyl)-oxy)-6-O-methyl-3-oxo-12,11-(oxycarbonyl-((4-(4-(4-fluorophenyl)-1 H-imidazol-1-yl)-butyl)-imino)]-erythromycin,

11,12-dideoxy-3-de-[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopy ranosyl)-oxy)-6-O-methyl-3-oxo-12,11-(oxycarbonyl-((4-(7-methoxy-4-quinolei nyl)-butyl)-imino)]-erythromycin,

11,12-dideoxy-3-de-[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopy ranosyl)-oxy)-6-O-methyl-3-oxo-12,11-(oxycarbonyl-((4-(2-(2-pyridinyl)-4-th iazolyl)-butyl)-imino)]-erythromycin,

11,12-dideoxy-3-de-[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopy ranosyl)-oxy)-6-O-methyl-3-oxo-12,11-(oxycarbonyl-((4-(3-(3-pyridinyl)-1H-1 ,2,4-triazol-1-yl)-butyl)-imino)]-erythromycin,

and their non-toxic, pharmaceutically acceptable acid addition salts.

19. A method of claim 11 wherein the compound is 11,12-dideoxy-3-de-[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexop yranosyl)-oxy)-6-O-methyl-3-oxo-12,11-(oxycarbonyl-((4-(4-(3-pyridinyl)-1H- imidazol-1-yl)-butyl)-imino)]-erythromycin.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc